收费全文 | 307919篇 |
免费 | 24316篇 |
国内免费 | 8661篇 |
耳鼻咽喉 | 1978篇 |
儿科学 | 6382篇 |
妇产科学 | 4016篇 |
基础医学 | 38695篇 |
口腔科学 | 5468篇 |
临床医学 | 27707篇 |
内科学 | 58212篇 |
皮肤病学 | 3499篇 |
神经病学 | 19147篇 |
特种医学 | 5538篇 |
外国民族医学 | 52篇 |
外科学 | 19648篇 |
综合类 | 39908篇 |
现状与发展 | 26篇 |
一般理论 | 12篇 |
预防医学 | 36592篇 |
眼科学 | 3304篇 |
药学 | 39173篇 |
128篇 | |
中国医学 | 11190篇 |
肿瘤学 | 20221篇 |
2024年 | 785篇 |
2023年 | 5692篇 |
2022年 | 11912篇 |
2021年 | 14910篇 |
2020年 | 12218篇 |
2019年 | 11488篇 |
2018年 | 10906篇 |
2017年 | 10147篇 |
2016年 | 9918篇 |
2015年 | 11190篇 |
2014年 | 18882篇 |
2013年 | 20989篇 |
2012年 | 18033篇 |
2011年 | 20343篇 |
2010年 | 16628篇 |
2009年 | 16674篇 |
2008年 | 16172篇 |
2007年 | 15021篇 |
2006年 | 12942篇 |
2005年 | 11004篇 |
2004年 | 9237篇 |
2003年 | 8078篇 |
2002年 | 6476篇 |
2001年 | 5539篇 |
2000年 | 4656篇 |
1999年 | 4123篇 |
1998年 | 3760篇 |
1997年 | 3427篇 |
1996年 | 3026篇 |
1995年 | 2757篇 |
1994年 | 2449篇 |
1993年 | 2131篇 |
1992年 | 1847篇 |
1991年 | 1670篇 |
1990年 | 1410篇 |
1989年 | 1251篇 |
1988年 | 1200篇 |
1987年 | 969篇 |
1986年 | 892篇 |
1985年 | 1510篇 |
1984年 | 1543篇 |
1983年 | 1058篇 |
1982年 | 1162篇 |
1981年 | 947篇 |
1980年 | 856篇 |
1979年 | 694篇 |
1978年 | 531篇 |
1977年 | 410篇 |
1976年 | 380篇 |
1975年 | 281篇 |
Research design and methods: This multicenter, open-label, single-group, prospective interventional study evaluated changes in total gait-related scores of the Part II/III Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Freezing of Gait Questionnaire (FOG-Q) in 31 Parkinson’s disease patients treated with istradefylline. Gait analysis by portable gait rhythmogram was performed.
Results: MDS-UPDRS Part III gait-related total scores significantly decreased at Weeks 4–12 from baseline with significant improvements in gait, freezing of gait, and postural stability. Significant decreases in MDS-UPDRS Part II total scores and individual item scores at Week 12 indicated improved daily living activities. At Week 12, there were significant improvements in FOG-Q, new FOG-Q, and overall movement per 48 h measured by portable gait rhythmogram. Adverse events occurred in 7/31 patients.
Conclusions: Istradefylline improved gait disorders in Parkinson’s disease patients complicated with freezing of gait, improving their quality of life. No unexpected adverse drug reactions were identified.
Trial registration: UMIN-CTR (UMIN000020288). 相似文献
Objectives
To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.Design
Cross-sectional survey.Method
An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.Results
Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.Conclusions
Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy. 相似文献Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献